A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
ApexOnco Front Page
Recent articles
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
PD-(L)1 x VEGF bispecifics prove a big draw.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
